DNA methylation is a biological process that adds methyl groups to DNA molecules. It regulates chromatin architecture and transcription, and plays essential roles in a wide range of biological processes (Li et al., 2013; Li et al., 2018; Roy et al., 2021). Accumulating evidence shows that the dysregulation of DNA methylation is involved in the development of many life-threatening diseases, including cancers, cardiovascular diseases (Pepin et al., 2019; Heery and Schaefer, 2021; Pepin et al., 2021; Dillinger et al., 2022; Rosselló-Tortella et al., 2022). This Research Topic aims to elucidate the correlation between DNA methylation and human diseases, with the hope to deepen our understanding of the underlying molecular mechanisms of DNA methylation in human diseases and pave the way to the development of new strategies or methods for disease prevention, diagnosis, and therapy. In total, there are 9 original research articles that have been published in this Research Topic.
In this Research Topic, we received articles in the fields of cancer biology, cardiac biology and covid research. Adding methyl groups to the C-5 position of cytosine, 5-methylcytosine, is the main type of DNA methylation (Choi et al., 2021), whose dysregulation has been reported to play roles in many types of cancer. To understand the 5-methylcytosine in cancer, one of the primary cause of death worldwide (Siegel et al., 2020), Liu et al. developed a 5-methylcytosine score system and evaluated tumor mutation burden, immune check-point inhibitor response, and the clinical prognosis of individual tumors using the score based on the 5-methylcytosine profile of 1,374 lung adenocarcinoma samples. Besides, by analyzing 5-methylcytosine and gene expression profiles from 860 clear cell renal cell carcinoma (ccRCC), Xu et al. found LINC00861 was the potentially intervening target of immunotherapy for prostate cancer patients and was significantly associated with the expression of PD-1 and CTLA4. Li et al. developed predictive diagnostic and prognostic models by using machine-learning and Cox regression approaches based on pancreatic adenocarcinoma (PAAD) datasets. To take the advantage of the third-generation sequencing technique, Zhang et al. collected two pairs of tumor tissues and adjacent normal tissues from hepatocellular carcinoma (HCC) surgical samples, and then conducted Nanopore sequencing. Zhang et al. identified four potential tumor suppressor genes (KCNIP4, CACNA1C, PACRG, and ST6GALNAC3) by the integrative analysis of 5-methycytosine and 6-methyladenine profiling. Their study provided a new solution for epigenetic regulation research and therapy of HCC. LncRNAs have been shown to have high tissue- and disease-specific expression patterns, which endows them the potential in therapy (Wapinski and Chang, 2011; Jiang et al., 2016; Jiang et al., 2019). Zhao et al. focused on lncRNAs differentially expressed in only one and multiple cancer types, and identified 29 lncRNAs as diagnostic biomarkers for ccRCC, the kidney renal papillary cell carcinoma (KIRP), and pan-cancer.
Dysregulated regulation of miRNAs has been shown to contribute to the pathogenesis of cardiovascular diseases (Shao et al., 2015; Dong et al., 2020; Qiu et al., 2020; Yang et al., 2020). To investigate the interaction between miR-29b and DNA methylation in cardiovascular diseases, Wu et al. collected heart tissue samples from 17 patients with congenital heart disease (CHD). The authors found an inversely correlation between miR-19a and DNA methyltransferases (DNMT) in the patients. Further exploration in hypomethylated zebrafish showed that miR-29b inhibitor relieved the deformity of hypomethylated zebrafish and restored the DNA methylation patterns in cardiomyocytes, resulting in increased proliferation and renormalization of gene expression, suggesting a mutual regulation between miR-29b and DNMTs in cardiomyocytes and supporting the miRNA-based therapy in cardiomyocytes.
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global public health crisis. To explore the roles of 5-Hydroxymethylcytosine in COVID-19, Chen et al. developed a machine learning model based on genome-wide 5-Hydroxymethylcytosine profiles in plasma cell-free DNA (cfDNA) from 53 healthy volunteers, 66 patients with moderate COVID-19, 99 patients with severe COVID-19, and 38 patients with critical COVID-19. They found 5-Hydroxymethylcytosine detected in cfDNA could be used as early warning markers for the disease progression and myocardial injury of COVID-19.
In summary, by taking the advantage of the state-of-the-art high-throughput sequencing technologies, the authors showed the function role of DNA methylation in various types of cancer, as well as in cardiovascular disease and COVID-19. We would like to thank all authors for their paper published in this Research Topic. These studies made significant contributions in the field, extending our understanding of the roles of DNA methylation in human disease and will facilitate further advancement. Nevertheless, studies investigating the dynamic changes of DNA methylation of human diseases and the potential of DNMT in disease therapeutics are still lacking, which might be the directions of future efforts in this Research Topic. In addition, the rapid development of sequencing technologies, such as nanopore DNA sequencing, will accelerate our research and discovery in this field.
Statements
Author contributions
SL and CJ wrote the manuscript. All authors listed approved it for publication.
Funding
This work was supported by Shanghai General Hospital Startup Funding (02.06.01.20.06).
Acknowledgments
We thank L. Tan, J. Wong, P. Adams, and H. Chen for their support and valuable discussions.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
Choi W. L. Mok Y. G. Huh J. H. (2021). Application of 5-methylcytosine DNA Glycosylase to the Quantitative Analysis of DNA Methylation. Int. J. Mol. Sci.22, 1072. 10.3390/ijms22031072
2
Dillinger T. Sheibani-Tezerji R. Pulverer W. Stelzer I. Hassler M. R. Scheibelreiter J. et al (2022). Identification of Tumor Tissue-Derived DNA Methylation Biomarkers for the Detection and Therapy Response Evaluation of Metastatic Castration Resistant Prostate Cancer in Liquid Biopsies. Mol. Cancer21, 1–8. 10.1186/s12943-021-01445-0
3
Dong Y. Xiao Y. Shi Q. Jiang C. (2020). Dysregulated lncRNA-miRNA-mRNA Network Reveals Patient Survival-Associated Modules and RNA Binding Proteins in Invasive Breast Carcinoma. Front. Genet.10, 1–14. 10.3389/fgene.2019.01284
4
Heery R. Schaefer M. H. (2021). DNA Methylation Variation along the Cancer Epigenome and the Identification of Novel Epigenetic Driver Events. Nucleic Acids Res.49, 12692–12705. 10.1093/nar/gkab1167
5
Jiang C. Ding N. Li J. Jin X. Li L. Pan T. et al (2019). Landscape of the Long Non-coding RNA Transcriptome in Human Heart. Briefings Bioinforma.20, 1812–1825. 10.1093/bib/bby052
6
Jiang C. Li Y. Zhao Z. Lu J. Chen H. Ding N. et al (2016). Identifying and Functionally Characterizing Tissue-specific and Ubiquitously Expressed Human lncRNAs. Oncotarget7, 7120–7133. 10.18632/oncotarget.6859
7
Li S. Zhang J. Huang S. He X. (2018). Genome-wide Analysis Reveals that Exon Methylation Facilitates its Selective Usage in the Human Transcriptome. Briefings Bioinforma.19, 754–764. 10.1093/bib/bbx019
8
Li Y. Xu J. Chen H. Zhao Z. Li S. Bai J. et al (2013). Characterizing Genes with Distinct Methylation Patterns in the Context of Protein-Protein Interaction Network: Application to Human Brain Tissues. PLoS ONE8, e65871. 10.1371/journal.pone.0065871
9
Pepin M. E. Ha C.-M. Crossman D. K. Litovsky S. H. Varambally S. Barchue J. P. et al (2019). Genome-wide DNA Methylation Encodes Cardiac Transcriptional Reprogramming in Human Ischemic Heart Failure. Lab. Invest.99, 371–386. 10.1038/s41374-018-0104-x
10
Pepin M. E. Ha C.-M. Potter L. A. Bakshi S. Barchue J. P. Haj Asaad A. et al (2021). Racial and Socioeconomic Disparity Associates with Differences in Cardiac DNA Methylation Among Men with End-Stage Heart Failure. Am. J. Physiology-Heart Circulatory Physiology320, H2066–H2079. 10.1152/AJPHEART.00036.2021
11
Qiu M. Fu Q. Jiang C. Liu D. (2020). Machine Learning Based Network Analysis Determined Clinically Relevant miRNAs in Breast Cancer. Front. Genet.11, 1–11. 10.3389/fgene.2020.615864
12
Rosselló-Tortella M. Bueno-Costa A. Martínez-Verbo L. Villanueva L. Esteller M. (2022). DNA Methylation-Associated Dysregulation of Transfer RNA Expression in Human Cancer. Mol. Cancer21, 1–8. 10.1186/s12943-022-01532-w
13
Roy R. Ramamoorthy S. Shapiro B. D. Kaileh M. Hernandez D. Sarantopoulou D. et al (2021). DNA Methylation Signatures Reveal that Distinct Combinations of Transcription Factors Specify Human Immune Cell Epigenetic Identity. Immunity54, 2465–2480. e5. 10.1016/j.immuni.2021.10.001
14
Shao T. Zhao Z. Wu A. Bai J. Li Y. Chen H. et al (2015). Functional Dissection of Virus-Human Crosstalk Mediated by miRNAs Based on the VmiReg Database. Mol. Biosyst.11, 1319–1328. 10.1039/c5mb00095e
15
Siegel R. L. Miller K. D. Jemal A. (2020). Cancer Statistics, 2020. CA A Cancer J. Clin.70, 7–30. 10.3322/caac.21590
16
Wapinski O. Chang H. Y. (2011). Long Noncoding RNAs and Human Disease. Trends Cell Biol.21, 354–361. 10.1016/J.TCB.2011.04.001
17
Yang Q. Wu F. Mi Y. Wang F. Cai K. Yang X. et al (2020). Aberrant Expression of miR‐29b‐3p Influences Heart Development and Cardiomyocyte Proliferation by Targeting NOTCH2. Cell Prolif.53, 1–16. 10.1111/cpr.12764
Summary
Keywords
DNA methylation, next-generation sequencing, human diseases, 5-methylcytosine (5mC), cancer
Citation
Jiang C and Li S (2022) Editorial: DNA Methylation Dynamics and Human Diseases. Front. Cell Dev. Biol. 10:956286. doi: 10.3389/fcell.2022.956286
Received
30 May 2022
Accepted
07 June 2022
Published
23 June 2022
Volume
10 - 2022
Edited and reviewed by
Ramani Ramchandran, Medical College of Wisconsin, United States
Updates
Copyright
© 2022 Jiang and Li.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Chunjie Jiang, chunjie.jiang917@outlook.com; Shengli Li, shengli.li@shsmu.edu.cn
This article was submitted to Molecular and Cellular Pathology, a section of the journal Frontiers in Cell and Developmental Biology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.